Loading organizations...
Key people at Innara Health.
Innara Health, based in Olathe, Kansas, develops neonatal care technologies, including its FDA-cleared NTrainer System, improving oral feeding skills in premature and newborn infants. Its products aim to reduce NICU length of stay and enhance quality of life for infants with developmental needs and their families. The company raised $14.93 million from investors like KCRise Fund and Flyover Capital, leading to its 2022 acquisition by a Fortune 500 company, advised by Outcome Capital. This acquisition coincided with the nationwide launch of its NTrainer System 2.0, following an April 2022 investment from Cardinal Health. Chris Mathia served as CEO from 2019; the company was founded in 2007 by D. Michael Litscher and David Stalling. Its business model centers on medical device sales and licensing, raised venture funding and received investments before acquisition.
Key people at Innara Health.
Innara Health develops neonatal care technologies, primarily the NTrainer System, the only FDA-cleared medical device that trains non-nutritive suck (NNS) skills in preterm and full-term infants to enable safer transitions from feeding tubes to breast or bottle feeding[1][2]. It serves hospitals, NICUs, clinicians, and families of premature infants, addressing weak oral feeding skills that prolong NICU stays and delay discharge—a key milestone recommended by the American Academy of Pediatrics[2][3]. The company has shown growth through clinical validation, hospital adoptions (e.g., AdventHealth Shawnee Mission), a simplified subscription pricing model, and a 2022 acquisition by Cardinal Health, which supports commercialization and aligns with neonatal nutrition goals[2][3][4].
Innara Health was established in 2007 to tackle critical feeding challenges in premature infants, with the NTrainer first designed in 2008[3][4]. CEO Chris Mathia leads the team, emphasizing resilience amid challenges like COVID-19, which paused scaling but enabled NTrainer upgrades for better NICU integration, smaller size, and global market readiness via proper device markings[3]. Early traction built through FDA clearance, clinical proof of reduced NICU stays, and partnerships, culminating in the April 2022 acquisition by Cardinal Health, validating its technology and boosting development[2][4].
Innara Health rides the neonatal healthtech wave, capitalizing on the U.S. prematurity epidemic—highest preterm rates since 2008—exacerbated by factors like COVID-19 reducing NICU access[3]. Timing aligns with demands for devices shortening hospital stays, optimizing outcomes, and cutting costs in an overburdened healthcare system[2][3]. Market forces favor it: FDA clearance, clinical evidence, and Cardinal Health's global reach position it to influence standards of care, expand internationally (overcoming prior patent roadblocks), and drive innovation in feeding health amid growing parental and clinician needs[2][3][4].
Post-2022 Cardinal Health acquisition, Innara Health is poised for accelerated commercialization of next-gen NTrainer, targeting global NICUs with subscription scalability and enhanced features[2][3][4]. Trends like rising preterm births, telehealth integration in neonatology, and emphasis on early interventions will propel growth, potentially reducing global NICU burdens. Its influence may evolve from niche innovator to standards-defining leader in neonatal feeding, delivering healthier starts for vulnerable infants—echoing its founding mission to transform preterm care[1][2].
